Dingjiu Bao

Statistics

Publications

Citations

1.1K

H-Index

Active since

1999

Affiliations

Genomics Institute of the Novartis Research Foundation(Current)

Novartis (United States)

San Francisco VA Medical Center

Ionis Pharmaceuticals (United States)

Dingjiu Bao is an author at Genomics Institute of the Novartis Research Foundation specializing in pharmacology, molecular pharmacology, and pharmacy.

Publications per year

1999–2020

Publications

Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice†

Xing Yu, Susan F. Murray, Sanjay K. Pandey et al. · Hepatology · 2005 · 303 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

David C. Tully, Paul V. Rucker, D. CHIANELLI et al. · Journal of Medicinal Chemistry · 2017 · 230 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Adenosine formed by 5′-nucleotidase mediates tubuloglomerular feedback

Scott C. Thomson, Dingjiu Bao, Aihua Deng et al. · Journal of Clinical Investigation · 2000 · 182 citations · Full text

Life Sciences, Nephrology, Physiology +16

Reduction of Hepatic and Adipose Tissue Glucocorticoid Receptor Expression With Antisense Oligonucleotides Improves Hyperglycemia and Hyperlipidemia in Diabetic Rodents Without Causing Systemic Glucocorticoid Antagonism

Lynnetta M. Watts, Vara Prasad Manchem, Thomas A. Leedom et al. · Diabetes · 2005 · 137 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis

D. CHIANELLI, Paul V. Rucker, Jason Roland et al. · Journal of Medicinal Chemistry · 2020 · 99 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

1–5 of 9